American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“Our new living guideline update, Treatment of Multiple Myeloma, is now available. New recommendations include that patients presenting high-risk smoldering multiple myeloma (SMM) choosing the right management strategy is critical to balancing efficacy with patient quality of life.
Current clinical recommendations support two primary approaches for this patient population:
Active Monitoring: Close, structured surveillance to detect early signs of progression.
Targeted Intervention: Treatment with daratumumab for a duration of up to 36 months.
Notably, routine use of lenalidomide is not recommended in this setting. Tailoring the approach to individual patient risk profiles and treatment goals remains essential.”
Title: Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Authors: Rahul Banerjee, Matthew C. Cheung, Benjamin Derman, Hans Messersmith, Samer Al Hadidi, Sita Bhella, Cynthia Chmielewski, Mohammad S. Ebraheem, C. Todd Kennedy, Shaji Kumar, Alan Langerak, Brea Lipe, Hira Mian, Eloisa Riva, Rahul Seth, Latha Subramanian, Saad Z. Usmani, Tanya M. Wildes, Saurabh Zanwar, Ying Zhuo, Lisa K. Hicks
Other articles about ASCO on OncoDaily.